Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology
Published: June 17, 2021
- More patients are surviving cancer or living longer with advanced disease thanks to the advent of novel cancer therapeutics and improved screening for cancer.
- Cancer treatments have been associated with cardiovascular toxicities that can express in both acute and in a delayed fashion. The development of cardiac arrhythmias is a complication of cancer therapeutics with unique challenges.
- This scientific statement summarizes current knowledge regarding arrhythmia identification and treatment in patients with cancer.
Supporting Materials
- Commentary: Arrhythmias and Autonomic Dysfunction in the Cancer Patient: Charting a New Path Into the Cardio-oncology Wilderness by Benjamin Noor, MD; Olujimi A. Ajijola, MD, PhD; Eric H. Yang, MD
- Top Things to Know: Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology
Recommended Reading
- Preclinical Models of Cancer Therapy–Associated Cardiovascular Toxicity
- Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications
- Use of human induced pluripotent stem-cell-derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing
- Cardio-Oncology: Vascular and Metabolic Perspectives
- Cardiovascular Disease and Breast Cancer: Where These Entities Intersect
- Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors